Pharmatest Services Ltd partners with Valirx Plc for GeneICE development
Pharmatest Services Ltd and Valirx Plc have signed a 3-year collaboration agreement related to the proprietary GeneICE technology of Valirx. During the project Pharmatest will be responsible for developing GeneICE products and testing their efficacy in Pharmatest’s preclinical cancer models.
Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. Valirx Plc is a London-based biopharmaceutical company developing technologies and products in oncology therapeutics and diagnostics.
Valirx’s proprietary GeneICE technology (“Gene inactivation by chromatin engineering”) enables selective silencing of rebellious genes contributing to many diseases, including cancer. In preliminary studies GeneICE products have been shown to be effective in prostate, ovarian, pancreatic and lung cancer cell lines.
Satu Vainikka, CEO of Valirx says: “Valirx is happy to enter into this 3-year agreement with Pharmatest. The work that Pharmatest has done for Valirx in our other programmes during the past years has been of very high quality and we are convinced that this agreement will substantially speed up the development of the GeneICE project.”
Jussi Halleen, CEO of Pharmatest comments: “This project continues our successful Eurostars-funded project D-SIST where we were partners with Valirx. I wish to thank Valirx for their trust in Pharmatest for continuing the collaboration and our fruitful business relationship in this very important project.”